Core Viewpoint - The Hong Kong Innovative Drug ETF managed by Penghua experienced a decline of 1.32% on December 2, with a trading volume of 27.97 million yuan, indicating a challenging market environment for innovative drug investments [1] Group 1: Fund Performance - The latest net asset value of the Hong Kong Innovative Drug ETF is 600 million yuan [1] - Since its inception on August 20, 2025, the fund has reported a return of -9.83% [1] - Over the past month, the fund has achieved a return of 0.66% [1] Group 2: Fund Management - The fund is managed by Penghua Fund Management Co., Ltd., with fund managers Lin Song and Zhang Yuxiang overseeing its operations [1] - The performance benchmark for the fund is the National Index of Hong Kong Innovative Drugs, adjusted for exchange rates [1] Group 3: Fund Size and Activity - The fund's shares increased by 2 million to a total of 666 million shares, despite a reduction of 16 million shares over the last 20 trading days [1]
12月2日港股创新药ETF鹏华（159286）份额增加200.00万份
Xin Lang Cai Jing·2025-12-03 01:11